September 22nd 2023
Cheryl VerStrate, DNP, AGPCNP-BC, OCN, explains the pitfalls with at-home genomic tests and why nurses must be ready to talk to their patients about genetic counseling.
2022 BURST Year in Review™: Reflecting on Recent Evidence for Testing in Patients with GI Cancers
View More
2nd Annual International Congress on Pediatric Oncology
View More
2022 BURST Year in Review™: How Has Recent Evidence in Testing Elevated Outcomes in Patients with Lung Cancers
View More
Community Practice Connections™: 23rd Annual International Lung Cancer Congress®
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
Register Now!
PER's Breast Cancer Symposia in San Antonio
Register Now!
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Register Now!
BURST CME™: Addressing Current Standards and Unmet Needs in Patients with Metastatic Breast Cancer
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
Register Now!
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Register Now!
New Targets, New Treatments, and New Combinations for the Management of Advanced Prostate Cancer
View More
BURST CME™: What Is the Real Risk in Lower-Risk MDS?
View More
BURST CME™: How Does Transfusion Burden Impact Real-World Outcomes in MDS?
View More
BURST CME™: Understanding Transfusion Dependence in Lower-Risk MDS
View More
How We Do It™: Integrating Gene Fusion Testing in Oncology Clinics for Patients with NSCLC
View More
Advances In™ KRAS Inhibition: Modern Considerations In Targeting KRAS-Mutated Lung, Colorectal, And Pancreatic Cancers
View More
The Latest on Acute Lymphocytic Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
A Focus on Acute Myeloid Leukemia
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Medical Crossfire®: Onco-Nursing Best Practices for Managing AEs Related to CAR T-Cell Therapy from Treatment Center to Community
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Medical Crossfire™: How Do We Implement Personalized Treatment for Colorectal Cancer in the Community?
View More
Medical Crossfire®: Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Medical Crossfire®: Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Medical Crossfire®: Exploring Hot Topics in DLBCL: Sequencing CD19-Targeted Therapies, Strategies Post-CAR T Relapse, Novel Agents, and More!
View More
Studies Yield More Insight Into Olaparib's Role in Ovarian Cancer
April 2nd 2015Analyses of clinical trials continue to illuminate the role of the PARP inhibitor olaparib (Lynparza) in the treatment of women with ovarian cancer, Ursula A. Matulonis, MD, explained during a plenary session at the 2015 Society of Gynecologic Oncology's Annual Meeting on Women's Cancer.
Dr. Hirshfield Discusses Screening Patients for Genetic Mutations
March 30th 2015Kim M. Hirshfield, MD, PhD, medical oncologist, Stacy Goldstein Breast Cancer Center, Rutgers Cancer Institute of New Jersey, discusses selecting individuals to screen for genetic mutations and the challenges of better selecting patients to screen.
Momentum Builds for National Plan for Precision Medicine
January 30th 2015During President Barack Obama's State of the Union Address last week, he announced a nationwide Precision Medicine Initiative that would help cure diseases such as cancer and diabetes. This morning he built on his announcement and outlined a $215 million plan to help develop precision medicine nationwide.
Joan Lunden and Dr Patrick Borgen Discuss Imaging and Genetic Testing in Breast Cancer
January 22nd 2015Joan Lunden talks about imaging technology and genetic testing for the early detection of breast cancer with Roy Firestone and Patrick I. Borgen, MD, in advance of her keynote address at the 32nd Miami Breast Cancer Conference (MBCC).
Investigators Find Potential Genetic Clues to Disparities in Colon Cancer
January 13th 2015Researchers from the Case Comprehensive Cancer Center have discovered new gene mutations that are unique to colon cancer in African American patients, who have the highest incidence and death rate from the disease.
Update on BRCA1/2: Technical and Policy Questions Arise as Testing Options Expand
January 2nd 2015As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing. In the past 18 months, the floodgates for testing options have opened, as companies seek to enter the diagnostic market in the wake of the US Supreme Court's June 2013 ruling that "naturally occurring" human genes are a "product of nature" and cannot be patented, breaking Myriad Genetics' monopoly on BRCA1/2 gene testing.
Olaparib Gets Approval for BRCA-Mutated Advanced Ovarian Cancer
December 20th 2014The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer. The approval was based on results from a single-arm phase II study of patients with deleterious or suspected deleterious germline BRCA-mutated advanced cancers
Dr. Chagpar Discusses Patient Perceptions of Genetic Testing's Impact on Health Insurance
December 19th 2014Anees B. Chagpar, MD, MSc, MA, MPH, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, program director, Interdisciplinary Breast Fellowship, assistant director, Diversity and Health Equity at Yale Cancer Center, discusses a study that looked at patient perceptions of the impact of genetic testing for breast cancer risk on health insurance.
Study Shows Over-the-Phone Genetic Counseling Is Effective
December 11th 2014For individuals living in rural areas, getting a genetic test can impose its own set of barriers, like multiple long trips for counseling, testing, and follow-up. However, findings of a new study published in the Journal of the National Cancer Institute have shown that telephone counseling was just as effective as in-person counseling in many respects.
PARP Inhibitor Demonstrates Clinical Activity in BRCA-Positive Patients
November 21st 2014The poly (ADP-ribose) polymerase (PARP) inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA–wild type tumors.
"Angelina Jolie Effect" Draws Attention to Genetic Counselor Model
September 3rd 2014With more and more data supporting the association between actress Angelina Jolie's double mastectomy and an increase in the amount of patients seeking genetic testing, the attention is on genetic counselors to improve their intake model to more efficiently handle the increased demand.
Is it Time to Think Outside the Box?: New Approaches to Genetics Services
August 28th 2014The demand for genetic services has never been greater. Vast advances in genetic technology, Angelina Jolie's disclosure that she is a BRCA mutation carrier, and the Supreme Court ruling on gene patents have hurled genetic services into the mainstream. Since the Supreme Court ruling last year, the cost of germline (hereditary) genetic testing has plummeted and now includes panels of genes.
For Breast Cancer Patients at Known BRCA Risk, a Role for Testing Prior to Surgery
June 17th 2014The majority of women with breast cancer who undergo the recommended genetic testing for BRCA1/2 mutations and test positive prior to undergoing surgery will change their surgical plan to include a more extensive procedure, a new study reports.
Survey Finds More Inquiries to Genetic Counselors, Including From the "Worried-Well"
June 9th 2014A recent survey conducted by the National Society of Genetic Counselors (NSGC) showed a significant increase in patient calls and requests for testing and referrals from healthcare providers in the year following actress Angelina Jolie's announcement of her BRCA mutation status and subsequent double mastectomy.
USPSTF, ASCO Issue More Guidance on Genetic Testing Based on Family History
April 24th 2014Oncology practitioners now have several resources to consult for advice on genetic testing for their patients following the US Preventive Services Task Force (USPSTF) December 2013 update of its 2005 BRCA recommendations, plus new recommendations from the American Socieity of Clinical Oncology (ASCO) announced in February and published in the Journal of Clinical Oncology.